News Author: Laura Nikolaides Publish date: October 23, 2015
News Author: Laura Nikolaides Publish date: October 22, 2015
The Food and Drug Administration approved irinotecan liposome injection, in combination with fluorouracil and leucovorin, to treat patients with metas...
News Author: Laura Nikolaides Publish date: October 14, 2015
News Author: Laura Nikolaides Publish date: October 13, 2015
News Author: Laura Nikolaides Publish date: October 2, 2015
Pembrolizumab had an overall response rate of 41%, and its effect lasted between 2.1 and 9.1 months.
News Author: Laura Nikolaides Publish date: October 2, 2015
Pembrolizumab had an overall response rate of 41%, and its effect lasted between 2.1 and 9.1 months.
News Author: Laura Nikolaides Publish date: August 18, 2015
News Author: Laura Nikolaides Publish date: June 4, 2015
Expert gives his take on bevacizumab, T-DM1, palbociclib, and neratinib.
Video Author: Laura Nikolaides Publish date: June 3, 2015
News Author: Laura Nikolaides Publish date: March 10, 2015
News Author: Laura Nikolaides Publish date: March 4, 2015
News Author: Laura Nikolaides Publish date: January 19, 2015
News Author: Laura Nikolaides Publish date: January 15, 2015
Key clinical point: This MEK inhibitor–associated cutaneous eruption can be treated with a drug holiday and oral corticosteroid treatment, r...
News Author: Laura Nikolaides Publish date: January 12, 2015
Key clinical point: Docetaxel every 3 weeks remains the standard treatment for elderly patients with advanced non–small cell lung cancer.
Ma...
News Author: Laura Nikolaides Publish date: January 10, 2015
Key clinical point: Increased imaging may identify low-volume recurrent disease that is unlikely to be clinically significant, leading to heighten...
